Abstract: Intake of flavonoids is associated with the incidence of breast cancer, but the association between the intake of flavonoids and cancer recurrence is unclear. This study aimed to investigate the hypothesis that intake of flavonoids and flavonoid-rich foods is negatively associated with cancer recurrence. Among 572 women who underwent breast cancer surgery, 66 patients had a cancer recurrence. Dietary data were collected using a structured 24-h dietary recall, and intake of flavonoids was calculated based on the Korea Rural Development Administration flavonoid database. Among overweight and obese patients, disease-free survival was associated with intake of flavonoids (p = 0.004) and flavonoid-rich foods (p = 0.003). Intake of flavonoids (hazard ratio (HR) = 0.249, 95% confidence interval (CI): 0.09–0.64) and flavonoid-rich foods (HR = 0.244, 95% CI: 0.09–0.66) was negatively associated with cancer recurrence after adjusting for confounding factors in overweight and obese patients. Consumption of flavonoids and flavonoid-rich foods was lower in overweight and obese patients with cancer recurrence than those without recurrence and in normal-weight patients. This study suggests that intake of flavonoids and flavonoid-rich foods could have beneficial effects on cancer recurrence in overweight and obese breast cancer survivors.

Keywords: breast cancer; flavonoids; flavonoid-rich foods; obesity; recurrence; survival

1. Introduction

Breast cancer is the most common cancer and the leading cause of cancer-related deaths among women worldwide [1]. Breast cancer recurrence leads to an increased risk of metastases and decreased survival [1]. Diet is a major modifiable risk factor for breast cancer incidence, recurrence, and mortality [2]. Our previous study showed that anti-inflammatory diets were related with cancer recurrence and overall mortality in breast cancer patients [3]. A meta-analysis of epidemiological studies reported that vegetable intake was negatively associated with cancer-related mortality [4] and breast cancer incidence [5]. Vegetables are the main source of flavonoids, including flavonols and flavones, which are natural antioxidants that reduce oxidative DNA damage [6].

Epidemiological studies have suggested that dietary intake of flavonols and flavones had a beneficial effect on the incidence of breast cancer [7–10]. Breast-cancer-specific mortality was also lower in those with the highest quintile of flavone intake than those with the lowest quintile of flavone intake [11]. However, Kyro et al. [12] showed no association between intake of flavonoids and breast-cancer-related mortality in patients with breast cancer. This inconsistency could partly be due to the effect of interaction between flavonoids and fat mass on the risk of breast cancer since intake of flavonoids was associated with weight loss in the Nurses’ Health Study [13] and lower body mass index (BMI) in a study using the National Health and Nutrition Examination Survey (NHANES) [14]. Bosetti et al. [7] observed that dietary intake of flavones was associated with incidence of breast cancer in participants with a BMI of ≥25 kg/m², but not in those with a BMI of <25 kg/m², suggesting that intake of flavonoids could be more beneficial for
obese breast cancer patients. Flavonoids have been shown to inhibit body fat accumulation by reducing the activity of fatty acid synthase (FAS) in obese mice fed a high-fat diet [15].

There has been no study evaluating the association between dietary intake of flavonoids and breast cancer recurrence. Therefore, this study aimed to investigate the hypothesis that dietary intake of flavonoids and flavonoid-rich foods is associated with cancer recurrence in patients with breast cancer. In addition, the association between flavonoid intake and cancer recurrence was compared between normal-weight and overweight/obese patients with breast cancer.

2. Materials and Methods

2.1. Patients

The study patients were recruited from a currently ongoing series of dietary survey projects on breast cancer. A total of 586 female patients who underwent breast cancer surgery at the breast cancer clinic of Hanyang University Seoul Hospital from March 2011 to April 2020 and who completed the dietary survey within five years from the date of breast cancer surgery were enrolled (Figure 1). Patients were excluded if they completed the dietary survey after cancer recurrence (n = 8) or if they had stage IV breast cancer (n = 6). After exclusion, 572 patients participated in the study.

![Flowchart of the study patient selection process.](image)

Patients were followed up from the date of surgery until the time of the first confirmed cancer recurrence, death, or the end of September 2020, whichever occurred first. Patients who were lost to follow-up were censored at the date of the last visit to the hospital. Recurrence included local or regional cancer recurrence, development of contralateral breast cancer, and distant metastasis. Local recurrence was defined as recurrence in the residual breast tissue or breast wall, and regional recurrence was defined as recurrence in the ipsilateral regional lymph nodes.

This study was conducted in accordance with the Declaration of Helsinki, and all procedures were approved by the Institutional Review Board of Hanyang University Hospital (HYU 2010-02-001-031) and Hanyang University (HYI-15-070). Before enrolment, written informed consent was obtained from all patients.

2.2. Data Collection

Data on age, height, body weight, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, histologic grade, tumor size, lymph node metastasis status, and type of treatment were obtained from the medical records and histopathology reports. Tumor and lymph node stages were
calculated according to the seventh edition of the American Joint Committee on Cancer (AJCC) staging system [16]. Overweight, obesity, and abdominal obesity were defined according to the Korean Society for the Study of Obesity [17].

Biochemical analyses were performed using blood samples collected from patients under fasting within a 2-month interval from the dietary survey. Serum levels of total protein, albumin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, white blood cell, hemoglobin, hematocrit, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, cholesterol, and cancer antigen 15-3 were obtained from the medical charts.

2.3. Intake of Dietary Flavonoids

A trained dietitian collected dietary data using a structured 24-h recall after breast cancer surgery, and dietary intake was analyzed using CAN-pro web, version 5.0 (computer-aided nutritional analysis program; Korean Nutrition Society, Seoul, Korea). Dietary intake of flavonols and flavones was estimated by matching 270 food items in the Korea Rural Development Administration flavonoid database [18]. Intake of flavonols and flavones was calculated by multiplying the content (mg) of flavonols and flavones by the amount of food (g) consumed by patients. Among the 165 foods consumed by our patients, foods rich in flavonols and flavones were defined as foods with a content of flavonols and flavones higher than the mean content of flavonols (>38.06 mg/100 g) or flavones (>62.01 mg/100 g) [19]. Flavonol-rich foods included green tea, castor aralia, red lettuce, butterbur, kale, mustard, onion, and seasoned cabbage, and flavone-rich foods included pepper leaf, mung bean, shepherd’s purse, Chinese cabbage, green pepper, red pepper, red lettuce, and celery.

2.4. Statistical Analyses

The Kolmogorov–Smirnov test was used to assess the normal distribution of the variables. Continuous variables are presented as mean ± standard deviation (SD). Differences between patients with and without cancer recurrence were verified using a one-way analysis of variance (ANOVA) or the Kruskal–Wallis test, followed by the least significant difference (LSD) post hoc test. Proportions of nominal variables, estimated using the chi-square test, are presented as the number of patients and percentage distribution. In the multivariate models, covariates with a p-value of < 0.20 were selected as confounding factors and included in the fully adjusted model [20]. Age, waist circumference, alcohol drinking, tumor size, lymph node metastasis, histological grade, and energy intake were identified as confounding factors. Biochemical evaluation of the blood samples was performed using a ranked one-way analysis of covariance (ANCOVA) after adjusting for confounding factors. The interactions between flavonoid intake and BMI were tested using a two-way ANOVA. Intake of flavonoids and flavonoid-rich foods was categorized into tertiles based on the distribution of patients, and the lowest tertiles of flavonoids and flavonoid-rich food intake were used in the reference group. The hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using multivariable Cox proportional hazards regression analysis after adjusting for confounding factors to evaluate the association between dietary intake of flavonoids/flavonoid-rich foods and breast cancer recurrence. The Kaplan–Meier method was used to calculate cumulative survival probabilities, and the difference between the survival curves was assessed using the log-rank test. All data analyses were performed using SPSS 25.0 (SPSS Inc., Chicago, IL, USA), and a p-value of <0.05 was considered statistically significant.

3. Results

3.1. Characteristics of Patients with Breast Cancer

Overweight and obese patients with cancer recurrence had a higher BMI and waist circumference, a larger tumor size, and more lymph node metastases than overweight and obese patients without cancer recurrence and normal-weight patients (Table 1). Patients with cancer recurrence were more likely to be current drinkers than those without cancer
reurrence. Moreover, overweight and obese patients without cancer recurrence were older than other patients. There were no significant differences in family history of breast cancer, smoking status, AJCC stage, type of treatment, histological grade, ER status, hormone receptor status, HER2 amplification status, and subtype between the groups (Table 1). All biochemical measurements were not significantly different between the patients (Table S1).

### Table 1. Characteristics of breast cancer patients with and without cancer recurrence.

| Variables                        | With Recurrence (n = 66) | Without Recurrence (n = 506) | p-Value 2 |
|----------------------------------|--------------------------|------------------------------|-----------|
|                                 | BMI < 23 (n = 33)        | BMI ≥ 23 (n = 33)            | BMI < 23 (n = 252) | BMI ≥ 23 (n = 254) |
| BMI (kg/m²)                      | 21.1 ± 1.3 a,b          | 26.5 ± 2.3 c                | 20.7 ± 1.5 a    | 25.7 ± 2.4 b    | <0.001 |
| Age (years)                      | 49.0 ± 9.5 a            | 51.5 ± 11.5 a               | 50.3 ± 9.7 a    | 53.8 ± 10.9 b   | <0.001 |
| WC (cm)                          | 70.5 ± 3.5 a            | 81.1 ± 6.6 c                | 70.1 ± 5.7 a    | 77.9 ± 6.5 b    | <0.001 |
| FH, n (%)                        | 4 (14.8)                | 4 (18.2)                    | 31 (13.9)       | 32 (13.8)       | 0.952  |
| Drinking, n (%)                  |                          |                              |                     |                      | 0.002  |
| Never                            | 16 (48.5)               | 25 (75.8)                   | 156 (61.9)       | 155 (61.3)       |        |
| Former                           | 8 (24.2)                | 3 (9.1)                     | 77 (30.6)       | 77 (30.4)       |        |
| Current                          | 9 (27.3)                | 5 (15.2)                    | 19 (7.5)        | 21 (8.3)        |        |
| Smoking, n (%)                   |                          |                              |                     |                      | 0.934  |
| Never                            | 31 (93.9)               | 32 (97.0)                   | 235 (93.3)      | 237 (93.7)      |        |
| Former                           | 2 (6.1)                 | 1 (3.0)                     | 13 (5.2)        | 11 (4.3)        |        |
| Current                          | 0 (0.0)                 | 0 (0.0)                     | 4 (1.6)         | 5 (2.0)         |        |
| Tumor, n (%)                     |                          |                              |                     |                      | 0.003  |
| <2 cm                            | 19 (57.6)               | 9 (27.3)                    | 155 (61.5)      | 139 (54.9)      |        |
| ≥2 cm                            | 14 (42.4)               | 24 (72.7)                   | 97 (38.5)       | 114 (45.1)      |        |
| Lymph node metastasis, n (%)     |                          |                              |                     |                      | 0.012  |
| Absence                          | 24 (72.7)               | 19 (57.6)                   | 197 (78.2)      | 171 (67.3)      |        |
| Presence                         | 9 (27.3)                | 14 (42.4)                   | 55 (21.8)       | 83 (32.7)       |        |
| AJCC, n (%)                      |                          |                              |                     |                      | 0.075  |
| Stages 0–2                       | 28 (84.4)               | 25 (75.8)                   | 226 (90.8)      | 220 (87.3)      |        |
| Stage 3                          | 5 (15.2)                | 8 (24.2)                    | 23 (9.2)        | 32 (12.7)       |        |
| Treatment, n (%)                 |                          |                              |                     |                      |        |
| Chemotherapy                      | 22 (66.7)               | 22 (68.8)                   | 124 (56.6)      | 126 (55.0)      | 0.331  |
| Hormonal therapy                 | 24 (72.7)               | 21 (65.6)                   | 169 (77.2)      | 165 (72.1)      | 0.427  |
| Radiotherapy                     | 11 (33.3)               | 15 (46.9)                   | 121 (55.3)      | 128 (55.9)      | 0.080  |
| Histologic grade, n (%)          |                          |                              |                     |                      | 0.405  |
| Grade 1                          | 8 (24.2)                | 4 (12.5)                    | 62 (26.1)       | 67 (27.3)       |        |
| Grade 2                          | 11 (33.3)               | 15 (46.9)                   | 103 (43.3)      | 108 (44.1)      |        |
| Grade 3                          | 14 (42.4)               | 13 (40.6)                   | 73 (30.7)       | 70 (28.6)       |        |
| ER-negative, n (%)               | 11 (33.3)               | 14 (42.4)                   | 71 (28.4)       | 77 (30.4)       | 0.413  |
| PR-negative, n (%)               | 12 (36.4)               | 17 (51.5)                   | 78 (31.2)       | 86 (34.0)       | 0.140  |
| HER2, n (%)                      |                          |                              |                     |                      | 0.705  |
| Not amplified                    | 23 (69.7)               | 21 (63.6)                   | 183 (73.2)      | 181 (71.5)      |        |
| Amplification                    | 10 (30.3)               | 12 (36.4)                   | 67 (26.8)       | 72 (28.5)       |        |
| Subtype, n (%)                   |                          |                              |                     |                      | 0.901  |
| HR+ /HER2−                      | 20 (60.6)               | 15 (45.5)                   | 151 (60.4)      | 145 (57.3)      |        |
| HR+ /HER2+                      | 6 (18.2)                | 8 (24.2)                    | 42 (16.8)       | 41 (16.2)       |        |
| HR− /HER2+                      | 4 (12.1)                | 4 (12.1)                    | 25 (10.0)       | 31 (12.3)       |        |
| HR− /HER2−                      | 3 (9.1)                 | 6 (18.1)                    | 32 (12.8)       | 36 (14.2)       |        |

BMI, body mass index; WC, Waist circumference; FH, Family history of breast cancer; Drinking status, smoking status, AJCC stage, American Joint Committee on Cancer; ER expression, estrogen receptor; PR expression, progesterone receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; 1 values are presented as mean ± standard deviation or number of patients (percentage distribution) accordingly; 2 p-values were analyzed using the Kruskal–Wallis test for continuous variables and the chi-square test for categorical variables; 3 values indicated using different superscript letters in the same row are significantly different at p < 0.05 according to ANOVA with the LSD post hoc test.
3.2. Association between Intake of Flavonoids/Flavonoid-Rich Foods and Cancer Recurrence

Overweight and obese patients with cancer recurrence had a lower intake of flavonoids, flavonols such as quercetin and kaempferol, and flavones such as apigenin and luteolin than other patients after adjusting for confounding factors (Table 2). Intake of flavonoid-rich foods, including flavonol-rich and flavone-rich foods, was consistently lower in overweight and obese patients with cancer recurrence than in other patients after adjusting for confounding factors (Table 2). However, there was no difference in intake of isorhamnetin between the patients. Additionally, there was a significant interaction between intake of flavonoids and flavonoid-rich food and BMI status on cancer recurrence, except for isorhamnetin intake. There was no significant association between intake of flavonoids and flavonoid-rich foods and cancer recurrence in all patients (Tables S2 and S3). However, among overweight and obese patients, intake of flavonoids, flavonols, and flavones, except isorhamnetin, was negatively associated with risk of cancer recurrence before and after adjusting for confounding factors (Table 3). The same association was consistently observed for flavonoid-rich foods, flavonol-rich foods, and flavone-rich foods (Table 4). Additionally, there was a negative association between risk of cancer recurrence and intake of flavonoids/flavonoid-rich foods as a continuous variable (Table 3; Table 4).

### Table 2. Consumption of flavonoids in patients with and without cancer recurrence.1

| Flavonoids (mg/d) | With Recurrence (n = 66) | Without Recurrence (n = 506) | p-Value 2 | p-Value for Flavonoids × BMI Interaction 4 |
|------------------|--------------------------|-----------------------------|----------|------------------------------------------|
|                  | BMI < 23 (n = 33)        | BMI ≥ 23 (n = 33)           |          |                                          |
| Flavonoids (mg/d)| 60.84 ± 34.03 b          | 30.62 ± 20.99 a             | 0.001    | 0.002                                    |
| Flavonols (mg/d) | 37.97 ± 29.21 b          | 18.32 ± 14.07 a             | 0.007    | 0.041                                    |
| Quercetin (mg/d) | 26.78 ± 17.99 ab         | 11.67 ± 13.43 a             | 0.018    | 0.008                                    |
| Kaempferol (mg/d)| 8.09 ± 6.83 ab           | 4.17 ± 3.35 a               | 0.011    | 0.030                                    |
| Isoflavonol (mg/d)| 3.10 ± 3.50             | 2.48 ± 2.22                 | 0.007    | 0.003                                    |
| Flavone (mg/d)   | 22.24 ± 12.51 b          | 12.29 ± 11.33 a             | 0.004    | 0.005                                    |
| Apigenin (mg/d)  | 9.09 ± 4.50 ab           | 4.61 ± 3.71 a               | 0.010    | 0.020                                    |
| Luteolin (mg/d)  | 8.91 ± 6.43 ab           | 7.68 ± 8.40 a               | 0.005    | <0.001                                   |
| Flavonoid-rich foods (g/d) | 101.33 ± 63.99 b | 61.77 ± 53.44 a | 0.025 | 0.009                                    |
| Flavonol-rich foods (g/d) | 65.63 ± 44.03 ab | 41.04 ± 42.30 a | 0.045 | 0.030                                    |
| Flavone-rich foods (g/d) | 35.70 ± 31.46 ab | 20.73 ± 24.23 a | 0.018 | 0.008                                    |

1 Values are presented as mean ± standard deviation; 2 p-values were determined by ranked analysis of variance for dietary intake of flavonoids or flavonoid-rich foods after adjusting for age, waist circumference, alcohol drinking, tumor size, lymph node metastasis, histologic grade, and energy intake; 3 values with different superscript letters in the same row are significantly different at p < 0.05, according to the ranked analysis of variance with the LSD post hoc test; 4 p-value for the interaction between flavonoids and BMI was determined using a two-way ANOVA; BMI, body mass index.

### Table 3. Association between dietary intake of flavonoids and cancer recurrence in overweight and obese patients.

| Flavonoids | T1 | T2 | T3 | p for Trend 1 |
|------------|----|----|----|--------------|
| Cutoff (mg/d) | 2.14 (≤3.15) | 4.27 (3.15 < to ≤ 5.78) | 8.51 (>5.78) | 0.001 |
| No. with/willout recurrence | 19/76 | 8/88 | 6/90 | 0.011 |
| Crude HR (95% CI) | 1.0 | 0.426 (0.18–0.97) | 0.299 (0.11–0.74) | 0.967 (0.95–0.98) |
| Adjusted HR (95% CI) 2 | 1.0 | 0.208 (0.08–0.52) | 0.249 (0.09–0.64) | 0.959 (0.93–0.98) |
| Cutoff (mg/d) | 0.91 (≤1.45) | 2.45 (1.45 < to ≤ 3.56) | 6.80 (>3.56) | 0.008 |
| No. with/willout recurrence | 18/78 | 9/86 | 6/90 | 0.026 |
| Crude HR (95% CI) | 1.0 | 0.479 (0.21–1.06) | 0.325 (0.12–0.82) | 0.945 (0.91–0.97) |
| Adjusted HR (95% CI) 2 | 1.0 | 0.299 (0.12–0.70) | 0.274 (0.09–0.76) | 0.943 (0.90–0.97) |

1 Values are presented as median (range); 2 p-values were determined by ranked analysis of variance for dietary intake of flavonoids or flavonoid-rich foods after adjusting for age, waist circumference, alcohol drinking, tumor size, lymph node metastasis, histologic grade, and energy intake; 3 values with different superscript letters in the same row are significantly different at p < 0.05, according to the ranked analysis of variance with the LSD post hoc test; 4 p-value for the interaction between flavonoids and BMI was determined using a two-way ANOVA; BMI, body mass index.
Table 3. Cont.

| Tertiles of Flavonoid Intake | T1          | T2          | T3          | p for Trend | Continuous |
|------------------------------|-------------|-------------|-------------|-------------|------------|
| No. with/without recurrence | 19/77       | 8/87        | 6/90        |             |            |
| Crude HR (95% CI) 1          | 1.0         | 0.441 (0.19–1.00) | 0.325 (0.13–0.81) | 0.041       | 0.972 (0.95–0.99) |
| Adjusted HR (95% CI) 2       | 1.0         | 0.353 (0.14–0.84) | 0.301 (0.11–0.82) | 0.047       | 0.966 (0.93–0.99) |
| Kaempferol Cutoff (range), 10 mg/d | 0.21 (≤0.33) | 0.46 (0.33 < to ≤0.75) | 1.25 (>0.75) |             |            |
| No. with/without recurrence | 19/76       | 8/89        | 6/89        |             |            |
| Crude HR (95% CI) 1          | 1.0         | 0.389 (0.17–0.88) | 0.275 (0.11–0.69) | 0.013       | 0.865 (0.77–0.96) |
| Adjusted HR (95% CI) 2       | 1.0         | 0.427 (0.17–1.04) | 0.268 (0.10–0.69) | 0.014       | 0.868 (0.78–0.96) |
| Isovitamin K cutoff (range), 10 mg/d | 0.09 (≤0.16) | 0.23 (0.16 < to ≤0.34) | 0.53 (>0.34) |             |            |
| No. with/without recurrence | 16/79       | 9/87        | 8/88        |             |            |
| Crude HR (95% CI) 1          | 1.0         | 0.533 (0.23–1.20) | 0.523 (0.22–1.22) | 0.167       | 0.899 (0.77–1.04) |
| Adjusted HR (95% CI) 2       | 1.0         | 0.523 (0.21–1.25) | 0.428 (0.17–1.03) | 0.080       | 0.901 (0.77–1.04) |
| Flavones Cutoff (range), 10 mg/d | 0.59 (≤1.01) | 1.50 (1.01 < to ≤2.04) | 2.62 (>2.04) |             |            |
| No. with/without recurrence | 19/76       | 8/88        | 6/90        |             |            |
| Crude HR (95% CI) 1          | 1.0         | 0.391 (0.17–0.89) | 0.290 (0.11–0.72) | 0.005       | 0.946 (0.91–0.98) |
| Adjusted HR (95% CI) 2       | 1.0         | 0.403 (0.16–0.98) | 0.337 (0.13–0.86) | 0.015       | 0.948 (0.91–0.98) |
| Apigenin Cutoff (range), 10 mg/d | 0.23 (≤0.45) | 0.67 (0.45 < to ≤0.89) | 1.30 (>0.89) |             |            |
| No. with/without recurrence | 20/76       | 7/88        | 6/90        |             |            |
| Crude HR (95% CI) 1          | 1.0         | 0.332 (0.14–0.78) | 0.266 (0.10–0.66) | 0.003       | 0.838 (0.73–0.95) |
| Adjusted HR (95% CI) 2       | 1.0         | 0.464 (0.18–1.14) | 0.317 (0.12–0.81) | 0.015       | 0.835 (0.71–0.95) |
| Luteolin Cutoff (range), 10 mg/d | 0.13 (≤0.45) | 0.86 (0.45 < to ≤1.30) | 1.35 (>1.30) |             |            |
| No. with/without recurrence | 17/79       | 10/85       | 6/90        |             |            |
| Crude HR (95% CI) 1          | 1.0         | 0.588 (0.26–1.28) | 0.315 (0.12–0.80) | 0.011       | 0.974 (0.95–0.99) |
| Adjusted HR (95% CI) 2       | 1.0         | 0.409 (0.17–0.93) | 0.315 (0.11–0.83) | 0.007       | 0.971 (0.94–0.99) |

1 Estimates of p-values for linear trends were based on linear scores derived from the medians of the tertiles of flavonoid intake in overweight and obese patients; 2 adjusted hazard ratio (HR) and 95% confidence interval (CI) were analyzed using Cox proportional hazards regression analysis after adjusting for age, waist circumference, alcohol drinking, tumor size, lymph node metastasis, histological grade, and energy intake.

3.3. Association between Intake of Flavonoids/Flavonoid-Rich Foods and Disease-Free Survival

Among overweight and obese patients with breast cancer, the median period of disease-free survival and overall survival was 43 months (range, 6–103 months; Figure 2a–f) and 72 months (range, 12–120 months), respectively (Figure S1a,b). Intake of flavonoids and flavonoid-rich foods was not significantly associated with disease-free survival and overall survival in all patients according to the Kaplan–Meier survival curves (Figure S2a–d). However, there was a significant correlation between dietary flavonoids, such as flavonols and flavones, and flavonoid-rich foods, such as flavonol-rich and flavone-rich foods, and disease-free survival in overweight and obese patients (Figure 2). Patients in the middle and highest tertiles of dietary flavonoids and flavone- and flavonoid-rich foods had longer survival than those in the lowest tertile (Figure 2a,c–f). Patients in the highest tertile of flavonol intake had prolonged survival compared to those in the lowest tertile (Figure 2b). Furthermore, intake of flavonoids and flavonoid-rich foods was not significantly associated with overall survival in overweight and obese patients (Figure S1a,b).
Figure 2. Cumulative disease-free survival according to the tertiles of flavonoid (a–c) or flavonoid-rich food intake (d–f) in overweight and obese patients with breast cancer. Statistical significance was determined using the log-rank test and the Kaplan–Meier method; *p < 0.05.

Table 4. Association between dietary intake of flavonoid-rich foods and cancer recurrence in overweight and obese patients.

| Flavonoid-rich food        | Tertiles of Flavonoid-Rich Food Intake | p for Trend 1 | Continuous |
|----------------------------|----------------------------------------|---------------|------------|
|                            | T1          | T2          | T3          |             |
| Flavonoid cutoff, 10 g/d   | 3.52 (≤5.99) | 9.25 (5.99 < to ≤12.54) | 16.75 (>12.54) |             |
| No. with/without recurrence| 19/75      | 8/85       | 6/91        |             |
| Crude HR (95% CI)         | 1.0        | 0.356 (0.15–0.81) | 0.285 (0.11–0.71) | 0.005 | 0.986 (0.97–0.99) |
| Adjusted HR (95% CI)      | 1.0        | 0.294 (0.11–0.72) | 0.244 (0.09–0.66) | 0.006 | 0.985 (0.97–0.99) |
| Flavonoid-rich food       |            |             |             |             |
| Flavonoid cutoff, 10 g/d   | 0.85 (≤3.74) | 5.95 (3.74 < to ≤8.24) | 11.95 (>8.24) |             |
| No. with/without recurrence| 17/75      | 9/87       | 7/92        |             |
| Crude HR (95% CI)         | 1.0        | 0.416 (0.18–0.93) | 0.339 (0.14–0.81) | 0.012 | 0.979 (0.96–0.99) |
| Adjusted HR (95% CI)      | 1.0        | 0.384 (0.16–0.88) | 0.321 (0.14–0.81) | 0.014 | 0.979 (0.95–0.99) |
| Flavonoid-rich food       |            |             |             |             |
| Flavonoid cutoff, 10 g/d   | 0.00 (≤1.79) | 2.80 (1.79 < to ≤4.49) | 6.80 (>4.49) |             |
| No. with/without recurrence| 19/72      | 9/91       | 5/91        |             |
| Crude HR (95% CI)         | 1.0        | 0.418 (0.18–0.92) | 0.260 (0.09–0.69) | 0.005 | 0.986 (0.97–0.99) |
| Adjusted HR (95% CI)      | 1.0        | 0.421 (0.18–0.97) | 0.284 (0.10–0.79) | 0.012 | 0.985 (0.97–0.99) |

1 Estimates of p-values for linear trends were based on linear scores derived from the medians of tertiles of flavonoid-rich food intake in overweight and obese patients; ∗ adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were analyzed using Cox proportional hazards regression analysis after adjusting for age, waist circumference, alcohol drinking, tumor size, lymph node metastasis, histological grade, and energy intake.
4. Discussion

This is the first study to show that dietary intake of flavonoids and flavonoid-rich foods was negatively associated with cancer recurrence among overweight and obese patients who underwent breast cancer surgery. No previous study has shown an association between dietary intake of flavonoids and the risk of breast cancer recurrence. However, a meta-analysis of epidemiological studies reported that intake of flavonols and flavones was negatively associated with the risk of breast cancer incidence [9]. Intake of flavonoid-rich foods, such as cauliflower, winter squash, spinach, carrots, pepper, garlic, onion, and beans, was also negatively associated with the incidence of breast cancer [21–25]. In addition, cancer recurrence was negatively associated with intake of vegetables [26], flavonoid-rich soy foods [27], and green tea [28] in breast cancer patients. In human breast cancer cells and xenograft animal models, flavonoids such as quercetin, kaempferol, apigenin, and luteolin have been shown to exert anti-cancer effects by inhibiting cell growth through apoptosis [29].

In previous epidemiological studies, the risk of breast cancer incidence was lower in participants with a higher than average intake of flavonoids in the United States [30] and in China [8]. The average intake of flavonoids is 23.0 mg/day in obese Korean women according to the Korea National Health and Nutrition Examination Survey (KNHANES) [31]. The present study showed that the risk of cancer recurrence was significantly lower in obese breast cancer patients with a higher than average intake of flavonoids. In addition, Feng et al. [32] showed that serum concentration of flavonoids was negatively associated with risk of breast cancer incidence. Jodynis-Liebert et al. [33] reported that high concentrations of flavonoids reduced tumor cell growth in an in vitro study. These results suggest that individuals should consume an amount of flavonoids higher than the average value to reduce not only the risk of incidence but also the recurrence of breast cancer.

In the present study, a significant interaction was observed between flavonoids and BMI status, suggesting that the effect of flavonoid intake on cancer recurrence might be different according to the BMI status of breast cancer patients. Previous studies observed that intake of flavonoids was negatively associated with the incidence of breast cancer in participants with BMI ≥ 25 kg/m², but not in those with BMI < 25 kg/m² [7]. In addition, a randomized controlled trial showed that supplementation of both flavonoid-rich green tea beverage and extract decreased body weight and BMI only in obese subjects [34]. BMI was correlated with plasma lipid peroxidation [35] and FAS expression [36] in obese patients but not in normal-weight patients. Lipid peroxidation [37] and FAS expression [38] were correlated with breast cancer recurrence in patients with breast cancer. Furthermore, flavonoids, as an antioxidant, increased apoptosis of cancer cells by reducing lipid peroxidation, reactive oxygen species, and DNA damage and by increasing superoxide dismutase [39] (Scheme 1). Flavonoids also inhibited lipid accumulation and FAS in breast cancer cells, suggesting that these anti-obesity effects of flavonoids increased the cytotoxicity of cancer cells [40]. Additionally, flavonoids’ immune regulation function is related to conversion of the adipocyte macrophage phenotype M1 (pro-inflammatory) to M2 (anti-inflammatory) [41]. Thus, the anti-inflammatory effect of flavonoids inhibits angiogenesis of cancer cells by decreasing inflammatory cytokines such as tumor necrosis factor-alpha, interleukin (IL)-1β, and IL-6 [42], and the anti-estrogen effect prevents metastasis of cancer cells by decreasing aromatase activity [43]. These studies support our results showing that intake of flavonoids can prevent cancer recurrence in overweight and obese patients.

In the present study, breast cancer recurrence was associated with intake of flavonols such as quercetin and kaempferol, but not with intake of isorhamnetin. Our patients consumed 78%, 15%, and 7% dietary flavonols in the form of quercetin, kaempferol, and isorhamnetin, respectively. Consistent with this, the KNHANES reported that Korean adults consumed 76%, 20%, and 4% dietary flavonols in the form of quercetin, kaempferol, and isorhamnetin, respectively. These results indicate that the effect of isorhamnetin on breast cancer might be weak because isorhamnetin contributes to the smallest proportion of flavonols [44]. Among the flavonols, the inhibitory effect on cell proliferation, cytotoxic
effects on cancer cells, and antioxidative effects of isorhamnetin were weaker than those of quercetin and kaempferol in human breast carcinoma cells [45,46].

Dietary intake of flavonoids [47] and vegetables [48] was negatively associated with all cancer-specific mortality. The survival of nude mice inoculated with breast cancer cells was also prolonged with increasing doses of flavonoids when administered orally [49]. In addition, mortality was lower in patients with breast cancer in the highest quintile of flavone intake than in those in the lowest quintile [11]. However, in patients with breast cancer, dietary intake of flavonoids and flavonoid-rich foods was not associated with mortality [11,12]. A meta-analysis of cohort studies and randomized controlled trials also showed that intake of vegetables was not associated with mortality and overall survival in patients with breast cancer [50]. Consistent with the previous studies, the present study showed no association between survival and flavonoid intake, but among obese patients, survival was associated with intake of flavonoids and flavonoid-rich foods.

The present study has a few limitations. First, the quantities of flavonoids in foods might differ according to the species, growth condition, and maturation, preparation, and food-processing methods [51]. These factors, which were not accounted for in the nutrient database, could contribute to random errors in the intake assessment and result in bias toward the null. In addition, flavonoid intakes were calculated based on the database, which had limited food coverage, and thus might be underestimated. Second, dietary intake was measured once through a 24-h recall, which might not be sufficient to determine the patient’s usual intake. Third, although adjustments were made for confounders, unmeasured factors such as the severity of comorbid diseases, lifelong eating behavior, and social factors including income and jobs could have affected the results of this study. Lastly, Ambrosone et al. [52] reported that the use of antioxidant supplements such as vitamin A and carotenoids was associated with an increased risk of cancer recurrence in breast cancer patients both before and during chemotherapy. Although there were no significant differences regarding the type of treatment, such as chemotherapy, hormone therapy, and radiation therapy, according to the flavonoid intake, the effect of flavonoids might be attenuated by some chemotherapeutic agents in the present study.
5. Conclusions

The present study showed that intake of flavonoids was associated with reduced risk of cancer recurrence, particularly in obese breast cancer patients, suggesting that increased consumption of flavonoid-rich foods could help prevent cancer recurrence. Further clinical studies are needed to confirm whether supplementation with flavonoids reduces cancer recurrence.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/nu13093049/s1, Supplement file 1: Figure S1. Survival curves according to tertiles of flavonoids or flavonoid-rich foods. Cumulative overall survival according to tertiles of flavonoids or flavonoid-rich foods in overweight and obese patients with breast cancer, Figure S2. Survival curves according to tertiles of flavonoids or flavonoid-rich foods. Cumulative disease-free survival and overall survival according to tertiles of flavonoids or flavonoid-rich foods in all patients with breast cancer, Supplement file 2: Table S1: Biochemical parameters in patients with and without cancer recurrence, Table S2: Association between dietary intake of flavonoids and cancer recurrence risk in all breast cancer patients, Table S3: Association between dietary intake of flavonoid-rich foods and cancer recurrence risk in breast cancer patients.

Author Contributions: M.C. (Minjung Cheon) conducted the study, performed the statistical analysis, and wrote the first draft. M.C. (Minsung Chung) analyzed the clinical data and revised the manuscript. Y.P. designed and supervised the study and finalized the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF-2021R1A2B5B02002208) and by grants (No. P016020012021) from the Rural Development Administration of Korea.

Institutional Review Board Statement: The project was approved by the Institutional Review Board of Hanyang University Hospital (HYU 2010-02-001-031) and Hanyang University (HYI-15-070).

Informed Consent Statement: Before enrolment, written informed consent was obtained from all patients.

Data Availability Statement: The dataset for this study is available from the corresponding author on reasonable request.

Acknowledgments: The authors are grateful to the patients and their caregivers for their involvement in this study.

Conflicts of Interest: The authors declare that they have no competing interests.

References
1. World Health Organization. WHO Report on Cancer: Setting Priorities, Investing Wisely and Providing Care for All; World Health Organization: Geneva, Switzerland, 2020; Available online: http://apps.who.int/iris/handle/10665/330745 (accessed on 27 March 2020).
2. Hamer, J.; Warner, E. Lifestyle modifications for patients with breast cancer to improve prognosis and optimize overall health. CMAJ 2017, 189, E268–e274. [CrossRef] [PubMed]
3. Jang, H.; Chung, M.S.; Kang, S.S.; Park, Y. Association between the dietary inflammatory index and risk for cancer recurrence and mortality among patients with breast cancer. Nutrients 2018, 10, 1095. [CrossRef] [PubMed]
4. Schwedhelm, C.; Boeing, H.; Hoffmann, G.; Aleksandrova, K.; Schwingshackl, L. Effect of diet on mortality and cancer recurrence among cancer survivors: A systematic review and meta-analysis of cohort studies. Nutr. Rev. 2016, 74, 737–748. [CrossRef] [PubMed]
5. Gandini, S.; Merzenich, H.; Robertson, C.; Boyle, P. Meta-analysis of studies on breast cancer risk and diet: The role of fruit and vegetable consumption and the intake of associated micronutrients. Eur. J. Cancer 2000, 36, 636–646. [CrossRef]
6. Martinez-Perez, C.; Ward, C.; Cook, G.; Mullen, P.; McPhail, D.; Harrison, D.J.; Langdion, S.P. Novel flavonoids as anti-cancer agents: Mechanisms of action and promise for their potential application in breast cancer. Biochem. Soc. Trans. 2014, 42, 1017–1023. [CrossRef] [PubMed]
7. Bosetti, C.; Spertini, L.; Parpinel, M.; Gnagnarella, P.; Lagoiu, P.; Negri, E.; Franceschi, S.; Montella, M.; Peterson, J.; Dwyer, J.; et al. Flavonoids and breast cancer risk in Italy. Cancer Epidemiol. Biomark. Prev. 2005, 14, 805–808. [CrossRef]
8. Feng, X.L.; Ho, S.C.; Mo, X.F.; Lin, F.Y.; Zhang, N.Q.; Luo, H.; Zhang, X.; Zhang, C.X. Association between flavonoids, flavonoid subclasses intake and breast cancer risk: A case-control study in China. Eur. J. Cancer Prev. 2020, 29, 493–500. [CrossRef] [PubMed]
9. Hui, C.; Qi, X.; Qianyong, Z.; Xiaoli, P.; Jundong, Z.; Mantian, M. Flavonoids, flavonoid subclasses and breast cancer risk: A meta-analysis of epidemiologic studies. *PloS ONE* 2013, 8, 54318. [CrossRef] [PubMed]
10. Rossi, M.; Bosetti, C.; Negri, E.; Lagiou, P.; La Vecchia, C. Flavonoids, proanthocyanidins, and cancer risk: A network of case-control studies from Italy. *Nutric. Cancer* 2010, 62, 871–877. [CrossRef]
11. Fink, B.N.; Steck, S.E.; Wolff, M.S.; Britton, J.A.; Kabat, G.C.; Gaudet, M.M.; Abrahamsson, P.E.; Bell, P.; Schroeder, J.C.; Teitelbaum, S.L.; et al. Dietary flavonoid intake and breast cancer survival among women on Long Island. *Cancer Epidemiol. Biomark. Prev.* 2007, 16, 2285–2292. [CrossRef]
12. Kyro, C.; Zamora-Ros, R.; Scalbert, A.; Tjonneland, A.; Dossus, L.; Johansen, C.; Bidstrup, P.E.; Weiderpass, E.; Christensen, J.; Ward, H.; et al. Pre-diagnostic polyphenol intake and breast cancer survival: The European prospective investigation into cancer and nutrition (EPIC) cohort. *Breast Cancer Res. Treat.* 2015, 154, 389–401. [CrossRef] [PubMed]
13. Bertoia, M.L.; Rimm, E.B.; Mukamal, K.J.; Hu, F.B.; Willett, W.C.; Cassidy, A. Dietary flavonoid intake and weight maintenance: Three prospective cohorts of 124,886 US men and women followed for up to 24 years. *BM* 2016, 352, i117. [CrossRef] [PubMed]
14. Vernarelli, J.A.; Lambert, J.D. Flavonoid intake is inversely associated with obesity and C-reactive protein, a marker for inflammation, in US adults. *Nutr. Diabetes* 2017, 7, e276. [CrossRef] [PubMed]
15. Wu, C.H.; Yang, M.Y.; Chan, K.C.; Chung, P.J.; Ou, T.T.; Wang, C.J. Improvement in high-fat diet-induced obesity and body fat accumulation by a nelumbo nucifera leaf flavonoid-rich extract in mice. *J. Agric. Food Chem.* 2010, 58, 7075–7081. [CrossRef] [PubMed]
16. Edge, S.B.; Compton, C.C. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann. Surg. Oncol.* 2010, 17, 1471–1474. [CrossRef]
17. Mi Hae, S.; Won-Young, L.; Sung Soo, K.; Jae-Heon, K.; Jee-Hyun, K.; Kyoung Kon, K.; Bo-Yeon, K.; Yang-Hyun, K.; Won-Jun, K.; Eun Mi, K.; et al. 2018 Korean society for the study of obesity guideline for the management of obesity in Korea. *J. Obes. Metab. Syndr.* 2019, 28, 40–45. [CrossRef]
18. Korea National Institute of Agricultural Sciences. Food and Nutrition Functional Information Flavonoid Ingredient Search. AVAILABLE ONLINE: http://koreanfood.rda.go.kr/kfi/fct/fctCompSrch/list (accessed on 31 March 2020).
19. Perez-Jimenez, J.; Neveu, V.; Vos, F.; Scalbert, A. Systematic analysis of the content of 502 polyphenols in 452 foods and beverages: An application of the phenol-explorer database. *J. Agric. Food Chem.* 2010, 58, 4959–4969. [CrossRef] [PubMed]
20. Greenland, S. Modeling and variable selection in epidemiologic analysis. *Am. J. Public Health* 1989, 79, 340–349. [CrossRef]
21. Farvid, M.S.; Chen, W.Y.; Rosner, B.A.; Tamimi, R.M.; Willett, W.C.; Eliassen, A.H. Fruit and vegetable consumption and breast cancer incidence: Repeated measures over 30 years of follow-up. *Int. J. Cancer* 2019, 144, 1496–1510. [CrossRef] [PubMed]
22. Chen, H.; Shao, F.; Zhang, F.; Miao, Q. Association between dietary carrot intake and breast cancer: A meta-analysis. *Medicine* 2018, 97, e12164. [CrossRef] [PubMed]
23. Do, M.H.; Lee, S.S.; Jung, P.J.; Lee, M.H. Intake of fruits, vegetables, and soy foods in relation to breast cancer risk in Korean women: A case-control study. *Nutr. Cancer* 2017, 57, 20–27. [CrossRef]
24. Challier, B.; Perarnau, J.M.; Viel, J.F. Garlic, onion and cereal fibre as protective factors for breast cancer: A French case-control study. *Eur. J. Epidemiol.* 1998, 14, 737–747. [CrossRef] [PubMed]
25. Adebamowo, C.A.; Cho, E.; Sampson, L.; Katan, M.B.; Spiegelman, D.; Willett, W.C.; Holmes, M.D. Dietary flavonols and flavonol-rich foods intake and the risk of breast cancer. *Int. J. Cancer* 2005, 114, 628–633. [CrossRef] [PubMed]
26. Thomson, C.A.; Rock, C.L.; Thompson, P.A.; Caan, B.J.; Cussler, E.; Flatt, S.W.; Pierce, J.P. Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: A secondary analysis from the women’s healthy eating and living study. *Breast Cancer Res. Treat.* 2011, 12.5, 519–527. [CrossRef] [PubMed]
27. Chi, F.; Wu, R.; Zeng, Y.C.; Xing, R.; Liu, Y.; Xu, Z.G. Post-diagnosis soy food intake and breast cancer survival: A meta-analysis of cohort studies. *Asian Pac. J. Cancer Prev.* 2013, 14, 2407–2412. [CrossRef] [PubMed]
28. Vincenza, G.; Daniele, N.; Angela, A.; Mattia, A.; Milena, V.; Massimo, M.; Stefano, R. Green tea consumption and risk of breast cancer recurrence—a systematic review and meta-analysis of observational studies. *Nutrients* 2018, 10, 1886. [CrossRef]
29. Huang, C.; Lu, C.K.; Tu, M.C.; Chang, J.H.; Chen, Y.J.; Tu, Y.H.; Huang, H.C. Polyphenol-rich Avicennia marina leaf extracts induce apoptosis in human breast and liver cancer cells and in a nude mouse xenograft model. *Oncotarget* 2019, 7, 35874–35893. [CrossRef] [PubMed]
30. Fink, B.N.; Steck, S.E.; Wolff, M.S.; Britton, J.A.; Kabat, G.C.; Schroeder, J.C.; Teitelbaum, S.L.; Neugut, A.I.; Gammon, M.D. Dietary flavonoid intake and breast cancer risk among women on Long Island. *Am. J. Epidemiol.* 2007, 165, 514–523. [CrossRef] [PubMed]
31. Oh, J.S.; Kim, H.; Vijayakumar, A.; Kwon, O.; Kim, Y.; Chang, N. Association of dietary flavonoid intake with prevalence of type 2 diabetes mellitus and cardiovascular disease risk factors in Korean women aged ≥30 years. *J. Nutr. Sci. Vitamionol.* 2017, 63, 51–58. [CrossRef] [PubMed]
32. Feng, X.-L.; Zhan, X.-X.; Zuo, L.-S.-Y.; Mo, X.-F.; Zhang, X.; Liu, K.-Y.; Li, L.; Zhang, C.-X. Associations between serum concentration of flavonoids and breast cancer risk among Chinese women. *Eur. J. Nutr.* 2021, 60, 1347–1362. [CrossRef] [PubMed]
33. Jodynis-Liebert, J.; Kujawska, M. Biphasic dose-response induced by phytochemicals: Experimental evidence. *J. Clin. Med.* 2020, 9, 718. [CrossRef]
34. Basu, A.; Sanchez, K.; Leyva, M.J.; Wu, M.; Betts, N.M.; Aston, C.E.; Lyons, T.J.; Basu, A.; Sanchez, K.; Leyva, M.J.; et al. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. *J. Am. Coll. Nutr.* 2010, 29, 31–40. [CrossRef]

35. Caimi, G.; Canino, B.; Montana, M.; Urso, C.; Calandrino, V.; Presti, R.L.; Hopps, E. Lipid peroxidation, protein oxidation, gelatinases, and their inhibitors in a group of adults with obesity. *Horm. Metab. Res.* 2019, 51, 389–395. [CrossRef]

36. Blüher, M.; Klöting, N.; Wueest, S.; Schoenle, E.J.; Schön, M.R.; Dietrich, A.; Fasshauer, M.; Stumvoll, M.; Konrad, D. Fas and FasL expression in human adipose tissue is related to obesity, insulin resistance, and type 2 diabetes. *J. Clin. Endocrinol. Metab.* 2014, 99, E36–E44. [CrossRef] [PubMed]

37. Herrera, A.C.; Victorino, V.J.; Campos, F.C.; Verenitach, B.D.; Lemos, L.T.; Aranome, A.M.; Oliveira, S.R.; Cecchini, A.L.; Simão, A.N.; Abdelhay, E.; et al. Impact of tumor removal on the systemic oxidative profile of patients with breast cancer discloses lipid peroxidation at diagnosis as a putative marker of disease recurrence. *Clin. Breast Cancer* 2014, 14, 451–459. [CrossRef] [PubMed]

38. Alo, P.L.; Visca, P.; Marci, A.; Mangoni, A.; Botti, C.; Di Tondo, U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. *Cancer* 1996, 77, 474–482. [CrossRef]

39. Padmavathi, R.; Senthilnathan, P.; Chodon, D.; Sakthisekaran, D. Therapeutic effect of paclitaxel and propolis on lipid peroxidation and antioxidant system in 7,12 dimethyl benz(a)anthracene-induced breast cancer in female sprague dawley rats. *Life Sci.* 2006, 78, 2820–2825. [CrossRef]

40. Brusselmans, K.; Vrolix, R.; Verhoeven, G.; Swinnen, J.V. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. *J. Biol. Chem.* 2005, 280, 5636–5645. [CrossRef] [PubMed]

41. Saqib, U.; Sarkar, S.; Suk, K.; Mohammad, O.; Baig, M.S.; Savai, R. Phytochemicals as modulators of M1-M2 macrophages in inflammatory *OncoTarget* 2018, 9, 17937–17950. [CrossRef] [PubMed]

42. Aryappalli, P.; Al-Qubaisi, S.S.; Attoub, S.; George, J.A.; Arafat, K.; Ramadi, K.B.; Mohamed, Y.A.; Al-Dhaferi, M.M.; Al-Sbiei, A.; Fernandez-Cabezudo, M.J.; et al. The IL-6/STAT3 signaling pathway is an early target of manuka honey-induced suppression of human breast cancer cells. *Front Oncol.* 2017, 7, 167. [CrossRef] [PubMed]

43. Park, Y.J.; Choo, W.H.; Kim, H.R.; Chung, K.H.; Oh, S.M. Inhibitory aromatase effects of flavonoids from ginkgo biloba extracts on estrogen biosynthesis. *Asian Pac. J. Cancer Prev.* 2015, 16, 6317–6325. [CrossRef] [PubMed]

44. Jun, S.; Shin, S.; Joung, H. Estimation of dietary flavonoid intake and major food sources of Korean adults. *Br. J. Nutr.* 2016, 115, 480–489. [CrossRef] [PubMed]

45. Wu, Q.; Kroon, P.A.; Shao, H.; Needs, P.W.; Yang, X. Differential effects of quercetin and two of its derivatives, isorhamnetin and isorhamnetin-3-glucuronide, in inhibiting the proliferation of human breast-cancer MCF-7 cells. *J. Agric. Food Chem.* 2018, 66, 7181–7189. [CrossRef] [PubMed]

46. Hämäläinen, M.; Nieminen, R.; Vuorela, P.; Heinonen, M.; Moilanen, E. Anti-inflammatory effects of flavonoids: Genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. *Mediators Inflamm.* 2007, 2007, 45673. [CrossRef] [PubMed]

47. Bondonno, N.P.; Dalgaard, F.; Kyrø, C.; Murray, K.; Bondonno, C.P.; Lewis, J.R.; Gislason, G.; Scalbert, A.; Cassidy, A.; et al. Flavonoid intake is associated with lower mortality in the Danish diet cancer and health cohort. *Clin. Breast Cancer* 2017, 17, E36–E44. [CrossRef] [PubMed]

48. Oyinlola, O.; Vanessa, G.-D.; Alice, W.; Jennifer S, M. Fruit and vegetable consumption and all-cause, cancer and CVD mortality: a systematic review and meta-analysis. *Nutrients* 2018, 10, 66. [CrossRef] [PubMed]

49. Zhu, J.; Zhang, H.; Zhu, Z.; Zhang, Q.; Ma, X.; Cui, Z.; Yao, T. Effects and mechanism of flavonoids from astragalus complanatus on breast cancer growth. *Arch. Pharmacal. Res.* 2015, 38, 965–972. [CrossRef] [PubMed]

50. He, J.; Gu, Y.; Zhang, S. Consumption of vegetables and fruits and breast cancer survival: A systematic review and meta-analysis. *Sci. Rep.* 2017, 7, 599. [CrossRef]

51. Rodríguez-García, C.; Sánchez-Quesada, C.; J, J.G. Dietary flavonoids as cancer chemopreventive agents: An updated review of human studies. *Antioxidants* 2019, 8, 137. [CrossRef]

52. Ambrosone, C.B.; Zipoli, G.R.; Hutson, A.D.; McCann, W.E.; McCann, S.E.; Barlow, W.E.; Kelly, K.M.; Cannieoto, R.; Sucheston-Campbell, L.E.; Hershman, D.L.; et al. Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221). *J. Clin. Oncol.* 2019, 38, 804–814. [CrossRef]